Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Zalicus Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for the Treatment of Pain



  Zalicus Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers
  for the Treatment of Pain

Preclinical Data on Z160 and Z944 Presented at the American Pain Society 2013
                                Annual Meeting

Business Wire

CAMBRIDGE, Mass. -- May 10, 2013

Zalicus Inc. (Nasdaq Capital Market: ZLCS) today announced that preclinical
data highlighting its novel, oral ion channel programs for the treatment of
pain including Z160, an N-type calcium channel blocker and Z944, a T-type
calcium channel blocker were presented at the 32nd Annual Scientific Meeting
of the American Pain Society taking place May 8-11, 2013 in New Orleans, LA.

“These data demonstrate the significant progress we have made in validating
the activity of our two most advanced novel, oral calcium channel blockers in
preclinical models of pain,” commented Mark H.N. Corrigan, MD, President and
CEO of Zalicus. “Our primary focus is on advancing the development of our ion
channel programs, including Z160, our first-in-class, oral N-type calcium
channel blocker for the treatment of chronic neuropathic pain that is
currently actively enrolling two Phase 2 clinical trials, and Z944, a novel
oral T-type calcium channel blocker that is continuing to progress in the
clinic.”

In a poster presentation entitled “Z160: A potent and state-dependent, small
molecule blocker of N-type calcium channels effective in nonclinical models of
neuropathic pain,” Margaret S. Lee, PhD, Vice President of Research &
Translational Medicine at Zalicus, presented preclinical pharmacology data
demonstrating that Z160:

  * Potently and selectively blocked N-type channel activity
  * Provided greater potency at elevated stimulus frequencies, similar to
    those typical of neurons processing pain signals
  * Preferentially enhanced the inactivated state, a mechanism distinct from
    that of other neuropathic pain drugs or N-type blockers
  * Performed with robust activity across a wide range of preclinical pain
    models with efficacy similar to currently marketed neuropathic pain drugs
    and no sedative effects.

In a poster presentation entitled “Z944: A first in-class T-type calcium
channel blocker effective in nonclinical models of acute and inflammatory
pain,” Glenn F. Short III, PhD, Senior Director of Research at Zalicus,
presented preclinical data demonstrating that Z944:

  * Potently and selectively blocked T-type channel activity
  * Exhibited selectivity for the inactivated state and was more active during
    higher frequency signaling
  * Displayed potent activity in preclinical models of pain, particularly
    inflammatory pain, with efficacy exceeding naproxen

About Z160 and N-type Calcium Channel Blockers

Z160 is a first-in-class, oral, state-dependent, selective N-type calcium
channel (Cav2.2) blocker, designed to selectively target neuronal pain
signaling by modulating neurons that are undergoing high-frequency firing.
Z160 has demonstrated efficacy in multiple animal models of neuropathic and
inflammatory pain, suggesting that it has the potential to treat a broad range
of chronic pain conditions. Additionally, clinical trials in over 200 subjects
have established Z160 as a safe and well tolerated drug candidate. N-type
calcium channels have been recognized as crucial targets in controlling pain
because of their key role in transmitting pain through the spinal nerves to
the brain. Zalicus has advanced Z160 into two Phase 2 proof-of-concept
clinical studies in chronic neuropathic pain and plans to report top-line data
in late 2013.

About Z944 and T-type Calcium Channel Blockers

Z944 is a novel, oral, state-dependent, selective T-type calcium channel
blocker that has demonstrated preclinical efficacy in multiple inflammatory
pain models. T-type calcium channels have been recognized as key targets for
therapeutic intervention in a broad range of cell functions and have been
implicated in pain signaling. Zalicus completed Phase 1 single and multiple
ascending dose clinical studies evaluating the safety and tolerability of Z944
in late 2012 and plans to continue further clinical development during 2013.

About Zalicus

Zalicus Inc. (Nasdaq Capital Market: ZLCS) is a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain.
Zalicus has a portfolio of proprietary clinical-stage product candidates
targeting pain such as Z160 and Z944 and has entered into multiple
revenue-generating collaborations with large pharmaceutical companies relating
to other products, product candidates and drug discovery technologies. Zalicus
applies its expertise in the discovery and development of selective ion
channel modulators and its combination high throughput screening capabilities
to discover innovative therapeutics for itself and its collaborators in the
areas of pain, inflammation, oncology and infectious disease. To learn more
about Zalicus, please visit www.zalicus.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its
product candidates, their potential and the plans for their clinical and
preclinical development, the Zalicus selective Ion channel modulation
technology and related preclinical product candidates and its other business
plans. These forward-looking statements about future expectations, plans,
objectives and prospects of Zalicus and its product candidates may be
identified by words like "believe," "expect," "may," "will," "should," "seek,"
“plan” or “could” and similar expressions and involve significant risks,
uncertainties and assumptions, including risks related to the development and
regulatory approval of Zalicus’ product candidates, including risks relating
to formulation and clinical development of Z160 and Z944, the unproven nature
of the Zalicus drug discovery technologies, the Company's ability to obtain
additional financing or funding for its research and development, and those
other risks that can be found in the "Risk Factors" section of Zalicus' annual
report on Form 10-K on file with the Securities and Exchange Commission and
the other reports that Zalicus periodically files with the Securities and
Exchange Commission. Actual results may differ materially from those Zalicus
contemplated by these forward-looking statements. These forward-looking
statements reflect management’s current views and Zalicus does not undertake
to update any of these forward-looking statements to reflect a change in its
views or events or circumstances that occur after the date of this release
except as required by law.

(c) 2013 Zalicus Inc. All rights reserved.

Contact:

Zalicus Inc.
Justin Renz, CFO, 617-301-7575
JRenz@zalicus.com
or
Gina Nugent, 617-460-3579
gnugent@zalicus.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement